‘The most important medical breakthrough of the 20th century’: How the NIH funded stem cells

The Nobel Prize-winning research that led to the first stem cell therapy may have been funded by the NIH.

Bloomberg reported Tuesday that NIH Director Francis Collins has confirmed to members of Congress that he gave a grant to a company called Cell Technologies, which uses stem cells from human cells to treat neurological diseases.

“The grant is the most important biomedical breakthrough of today’s century,” Collins said.

“I am proud to be a part of it and to have contributed my knowledge to its completion.”

The grant was approved by the Office of Science of the National Institutes of Health, which is the U.S. government agency that provides scientific guidance and funding to the Department of Health and Human Services, according to its website.

It was awarded to Cell Technologies by the National Institute on Deafness and Other Communication Disorders, the NIH, the National Science Foundation and the National Cancer Institute.

Collins said in an email that he was not aware of any other recent grant recipients to be awarded a stem cell treatment.

Collins said the NIH has awarded more than $2.5 billion to stem cell research since 2004, including more than 20,000 grants for embryonic stem cells and embryonic stem cell therapies.

Cell Technologies had received a $2 million grant from the NIH in 2015 to develop an HIV treatment for adults with HIV, Collins said in the email.

He said the company also had received an additional $5 million from the National Center for Research Resources, the U-M Department of Medicine, the University of North Carolina at Chapel Hill, and the Broad Institute of MIT and Harvard.

The NIH awarded a $4 million grant in 2015 for a new HIV drug that is more effective than existing treatments, Collins added.

Collins has not commented publicly on his role in the Cell Technologies funding.

He has not responded to a request for comment on the new stem cell funding from Bloomberg.

The stem cell project was funded by a $3.8 million NIH grant, as part of the Advanced Research Projects Agency-Energy grant program, which also supports embryonic stem research.

Collins noted in the message that the $3 million grant is a one-time grant for Cell Technologies to develop a new type of stem cell.

Collins acknowledged in the NIH message that Cell Technologies was not the only company involved in the stem cell work.

“As a part, we have also had numerous discussions with other companies,” Collins wrote.

“The company has a long history of providing innovative stem cell treatments, including in a number of important areas.”

Cell Technologies, founded by former NIH director Francis Collins, has been involved in developing and developing therapies to treat a range of diseases.

The company has received several $2 billion awards, including the largest in 2016, which was for a vaccine for hepatitis B.

The Cell Technologies grant, which received $3,000, is the largest grant to stem cells to date, according a Reuters report.

It also is the first award to Cell Technology for any new type, according the report.

The project was approved in December 2017 by the U,N.

General Assembly.

The project, funded by U.N. funds, was initially announced as part and parcel of a U.K. government initiative to help the United States and Britain develop stem cell technologies.

The plan was to conduct clinical trials of stem cells for use in a variety of diseases including Parkinson’s disease, Parkinson’s-related glaucoma and spinal cord injuries.

The trial would be funded by $1 billion of U.NS funds.

The U.UK. government is now developing a stem cells program with the U of S, and is expected to start the trials in 2019, the report said.